MARCO ISLAND, Fla. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Priya Vakharia, MD, discusses phase 2 data for APX3330 for the treatment of diabetic retinopathy.
The trial did not meet its primary endpoint of two-step reduction on the Diabetic Retinopathy Severity Scale (DRSS). However, the data showed a trend of three-step worsening on the binocular DRSS scale among patients with DR who received placebo compared with those treated with APX3330, Vakharia said.
“This will hopefully guide a phase 3 trial looking at three-step worsening of